不同亚型贲门肠上皮化生与贲门癌关系的研究
|
摘要
目的:检测贲门肠上皮化生组织及贲门各级病变组织中Ki67、DAS-1及TFF3蛋白的表达变化,探讨不同亚型贲门肠上皮化生与贲门癌的相关性。
方法:收集河南省林州地区无症状人群胃镜普查贲门组织以及贲门癌手术标本共计170例。分为3组:贲门炎组织25例、肠化组织80例(包括无癌肠化组织15例,癌旁肠化组织65例)及贲门癌组织65例。采用免疫组织化学SP法,分别检测各组组织中Ki67、DAS-1及TFF3蛋白的表达情况;利用SPSS软件分析各组间Ki67、DAS-1及TFF3蛋白表达的差异。并采用粘液组织化学染色的方法对80例肠化组织进行分型,分析肠化亚型与贲门癌之间的相关性。
结果:在贲门炎、肠化组织及癌变组织中,Ki67蛋白阳性表达率分别为16.0%、43.8%和53.8%,经统计学分析Ki67蛋白表达在各组间的表达差异具有统计学意义,并与贲门炎组织、肠化、再至癌变这一病理变化过程呈正相关(r=0.436,P<0.05)。通过粘液组化染色分型,Ⅰ型、Ⅱ型、Ⅲ型在门诊胃镜活检无癌肠化组织及贲门癌癌旁肠化组织中所占比例分别为66.7%、20.0%、13.3%和13.8%、30.8%、55.4%,经统计学分析Ⅲ型贲门肠化在贲门癌癌旁肠化组织中所占的比例55.4%显著高于门诊胃镜活检无癌肠化组织13.3% (χ2=39.305,P <0.01)。DAS-1蛋白、TFF3蛋白在贲门炎、肠化组织及癌变组织中的阳性表达率分别为0%、38.8%、53.8%和24%、65%和53.8%,经统计学分析DAS-1蛋白在各组间的表达差异具有统计学意义,并与贲门组织的病理变化呈正相关(r=0.572,P<0.05);TFF3蛋白在贲门炎、肠化组织两组间的表达具有统计学意义(χ2=34.031,P<0.05),在肠化组织、癌组织两组间的表达无统计学意义(χ2=2.512,P>0.05)。在Ⅰ型、Ⅱ型和Ⅲ型贲门肠化组织中,DAS-1蛋白、TFF3蛋白的阳性表达率分别为0%、17.4%、71.1%和68.4%、78.4%、55.3%,经统计学分析DAS-1蛋白在各组间的表达具有明显差异,其中Ⅲ型显著高于Ⅰ型(χ2=110.078,P<0.01),TFF3蛋白在各组间的表达无统计学意义(χ2=12.033,P>0.05)。从形态学上分析,TFF3蛋白在贲门炎及Ⅰ型肠化组织中主要表达在柱状细胞的纹状缘,Ⅲ型肠化及癌变组织中主要表达在细胞质中,其表达的位点与病理类型相关(Kappa=0.490)。
结论:1、Ki67蛋白在贲门炎、肠化组织及癌变组织中表达率逐渐增高,表明随着组织学形态的改变,细胞的增殖能力逐渐增强。提示贲门肠上皮化生是贲门癌变过程中一个重要环节。2、DAS-1蛋白在贲门炎、肠化组织及癌变组织中的表达差异具有统计学意义,提示该蛋白有可能成为提高贲门癌早期诊断率的监测指标及预警分子。3、伴DAS-1过表达的Ⅲ型贲门肠化与贲门癌的关系密切,可能是河南贲门癌高发区GCA的一种重要的癌前病变。4、TFF3蛋白在贲门炎及Ⅰ型肠化组织中主要表达在柱状细胞的纹状缘,Ⅲ型肠化及癌变组织中主要表达在细胞质中,其表达位点的转变可能说明了该蛋白表现为抑癌和促癌两种不同作用的结构基础。
Objective: To identify the relationship between subtypes of cardia intestinal metaplasia and gastric cardia adenocarcinoma by analyzing the expression of Ki67, das-1 and TFF3 proteins in subtypes of cardia intestinal metaplasia and cardia lesions at all levels.
Methods: One hundred and seventy cases of cardia tissues by gastroscope and carida cancer tissues by surgery were collected in Linzhou area of Henan province. immunohistochemical S-P method has been employed to examine the expression of Ki67, das-1 and TFF3 proteins in 25 gastric cardia hilitis, 15 intestinal metaplasia without cancer, 65 intestinal metaplasia adjacent cancer 65 gastric cardia adenocarcinoma issue specimens. Eighty intestinal metaplasia issue specimens were typed by the Mucus staining method. The relationship between subtypes of cardia intestinal metaplasia and gastric cardia adenocarcinoma was analyzed by SPSS soft.
Results: The positive rates of Ki67 protein in gastric cardia hilitis, intestinal metaplasia, and carcinoma tissues were 16.0%, 43.8%, and 53.8%, respectively. Statistical analysis using chi-square showed the expression level of Ki67 protein was different and correlated well with the pathological grading of the lesions (r=0.436, P<0.05). Eighty cases of gastric cardia intestinal metaplasia were classified three types by mucosal staining. The proportion of typeⅢIM was significantly higher for IM foci in tissues adjacent to GCA (55.4%) than in gastric cardia biopsy tissues with IM from the outpatient (13.3%) (P<0.01). The positive rates of DAS-1 protein and TFF3 protein in gastric cardia hilitis, intestinal metaplasia, and carcinoma tissues were 0%, 38.8%, 53.8%, and 24%, 65%, 53.8% respectively. Statistical analysis using chi-square showed the expression level of DAS-1 protein was different and correlated well with the pathological grading of the lesions (r=0.572, P<0.05). For TFF3 protein, statistical significance of the positive rates was showed only between cardia hilitis and intestinal metaplasia(χ2=34.031, P<0.05). Among three types of intestinal metaplasia, The positive rates of DAS-1 and TFF3 were 0%, 17.4%, 71.1% and 68.4%, 78.4%, 55.3% respectively. The positive rates of DAS-1 in IM increased gradually from typeⅠto typeⅢ(χ2=110.078,P<0.01), and TFF3 protein expression was not statistically significant(χ2=12.033, P>0.05). In the cardia inflammation and intestinal metaplasia tissues, TFF3 protein was mainly expressed striated border in columnar cells while Intestinal metaplasia with dysplasia and cancerous tissue, mainly expressed in the cytoplasm. The location of TFF3 expression correlated with the pathological types (Kappa=0.490).
Conclusion: It is cardia intestinal metaplasia that prompted the course of carcinoma. It is because that the position rates of Ki67 protein in gastric cardia hilitis, intestinal metaplasia and cancerous tissue increased gradually, which indicated that the ability of cell differentiation reduced gradually with the histological changes gradually. Expression difference of Das-1 protein in the levels of gastric cardia tissues was involved in gastric cardia carcinogenesis and it could potentially become the important risk factors in detecting GCA. Furthermore, The typeⅢIM with over-expression of DAS-1 is closely related to GCA, which could potentially become one of important precancerous lesions for GCA at the high-incidence areas in Henan province. The transition in the location of TFF3 expression showed that the double role of TFF3 depends on its different expression location.
方法:收集河南省林州地区无症状人群胃镜普查贲门组织以及贲门癌手术标本共计170例。分为3组:贲门炎组织25例、肠化组织80例(包括无癌肠化组织15例,癌旁肠化组织65例)及贲门癌组织65例。采用免疫组织化学SP法,分别检测各组组织中Ki67、DAS-1及TFF3蛋白的表达情况;利用SPSS软件分析各组间Ki67、DAS-1及TFF3蛋白表达的差异。并采用粘液组织化学染色的方法对80例肠化组织进行分型,分析肠化亚型与贲门癌之间的相关性。
结果:在贲门炎、肠化组织及癌变组织中,Ki67蛋白阳性表达率分别为16.0%、43.8%和53.8%,经统计学分析Ki67蛋白表达在各组间的表达差异具有统计学意义,并与贲门炎组织、肠化、再至癌变这一病理变化过程呈正相关(r=0.436,P<0.05)。通过粘液组化染色分型,Ⅰ型、Ⅱ型、Ⅲ型在门诊胃镜活检无癌肠化组织及贲门癌癌旁肠化组织中所占比例分别为66.7%、20.0%、13.3%和13.8%、30.8%、55.4%,经统计学分析Ⅲ型贲门肠化在贲门癌癌旁肠化组织中所占的比例55.4%显著高于门诊胃镜活检无癌肠化组织13.3% (χ2=39.305,P <0.01)。DAS-1蛋白、TFF3蛋白在贲门炎、肠化组织及癌变组织中的阳性表达率分别为0%、38.8%、53.8%和24%、65%和53.8%,经统计学分析DAS-1蛋白在各组间的表达差异具有统计学意义,并与贲门组织的病理变化呈正相关(r=0.572,P<0.05);TFF3蛋白在贲门炎、肠化组织两组间的表达具有统计学意义(χ2=34.031,P<0.05),在肠化组织、癌组织两组间的表达无统计学意义(χ2=2.512,P>0.05)。在Ⅰ型、Ⅱ型和Ⅲ型贲门肠化组织中,DAS-1蛋白、TFF3蛋白的阳性表达率分别为0%、17.4%、71.1%和68.4%、78.4%、55.3%,经统计学分析DAS-1蛋白在各组间的表达具有明显差异,其中Ⅲ型显著高于Ⅰ型(χ2=110.078,P<0.01),TFF3蛋白在各组间的表达无统计学意义(χ2=12.033,P>0.05)。从形态学上分析,TFF3蛋白在贲门炎及Ⅰ型肠化组织中主要表达在柱状细胞的纹状缘,Ⅲ型肠化及癌变组织中主要表达在细胞质中,其表达的位点与病理类型相关(Kappa=0.490)。
结论:1、Ki67蛋白在贲门炎、肠化组织及癌变组织中表达率逐渐增高,表明随着组织学形态的改变,细胞的增殖能力逐渐增强。提示贲门肠上皮化生是贲门癌变过程中一个重要环节。2、DAS-1蛋白在贲门炎、肠化组织及癌变组织中的表达差异具有统计学意义,提示该蛋白有可能成为提高贲门癌早期诊断率的监测指标及预警分子。3、伴DAS-1过表达的Ⅲ型贲门肠化与贲门癌的关系密切,可能是河南贲门癌高发区GCA的一种重要的癌前病变。4、TFF3蛋白在贲门炎及Ⅰ型肠化组织中主要表达在柱状细胞的纹状缘,Ⅲ型肠化及癌变组织中主要表达在细胞质中,其表达位点的转变可能说明了该蛋白表现为抑癌和促癌两种不同作用的结构基础。
Objective: To identify the relationship between subtypes of cardia intestinal metaplasia and gastric cardia adenocarcinoma by analyzing the expression of Ki67, das-1 and TFF3 proteins in subtypes of cardia intestinal metaplasia and cardia lesions at all levels.
Methods: One hundred and seventy cases of cardia tissues by gastroscope and carida cancer tissues by surgery were collected in Linzhou area of Henan province. immunohistochemical S-P method has been employed to examine the expression of Ki67, das-1 and TFF3 proteins in 25 gastric cardia hilitis, 15 intestinal metaplasia without cancer, 65 intestinal metaplasia adjacent cancer 65 gastric cardia adenocarcinoma issue specimens. Eighty intestinal metaplasia issue specimens were typed by the Mucus staining method. The relationship between subtypes of cardia intestinal metaplasia and gastric cardia adenocarcinoma was analyzed by SPSS soft.
Results: The positive rates of Ki67 protein in gastric cardia hilitis, intestinal metaplasia, and carcinoma tissues were 16.0%, 43.8%, and 53.8%, respectively. Statistical analysis using chi-square showed the expression level of Ki67 protein was different and correlated well with the pathological grading of the lesions (r=0.436, P<0.05). Eighty cases of gastric cardia intestinal metaplasia were classified three types by mucosal staining. The proportion of typeⅢIM was significantly higher for IM foci in tissues adjacent to GCA (55.4%) than in gastric cardia biopsy tissues with IM from the outpatient (13.3%) (P<0.01). The positive rates of DAS-1 protein and TFF3 protein in gastric cardia hilitis, intestinal metaplasia, and carcinoma tissues were 0%, 38.8%, 53.8%, and 24%, 65%, 53.8% respectively. Statistical analysis using chi-square showed the expression level of DAS-1 protein was different and correlated well with the pathological grading of the lesions (r=0.572, P<0.05). For TFF3 protein, statistical significance of the positive rates was showed only between cardia hilitis and intestinal metaplasia(χ2=34.031, P<0.05). Among three types of intestinal metaplasia, The positive rates of DAS-1 and TFF3 were 0%, 17.4%, 71.1% and 68.4%, 78.4%, 55.3% respectively. The positive rates of DAS-1 in IM increased gradually from typeⅠto typeⅢ(χ2=110.078,P<0.01), and TFF3 protein expression was not statistically significant(χ2=12.033, P>0.05). In the cardia inflammation and intestinal metaplasia tissues, TFF3 protein was mainly expressed striated border in columnar cells while Intestinal metaplasia with dysplasia and cancerous tissue, mainly expressed in the cytoplasm. The location of TFF3 expression correlated with the pathological types (Kappa=0.490).
Conclusion: It is cardia intestinal metaplasia that prompted the course of carcinoma. It is because that the position rates of Ki67 protein in gastric cardia hilitis, intestinal metaplasia and cancerous tissue increased gradually, which indicated that the ability of cell differentiation reduced gradually with the histological changes gradually. Expression difference of Das-1 protein in the levels of gastric cardia tissues was involved in gastric cardia carcinogenesis and it could potentially become the important risk factors in detecting GCA. Furthermore, The typeⅢIM with over-expression of DAS-1 is closely related to GCA, which could potentially become one of important precancerous lesions for GCA at the high-incidence areas in Henan province. The transition in the location of TFF3 expression showed that the double role of TFF3 depends on its different expression location.
引文
[1] Wu X, Chen VW, Andrews PA, et al. Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences[J]. Cancer Causes Control. 2007, 18 (6): 585-593.
[2] Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by histology, United States, 1998-2003[J]. Int J Cancer. 2008, 123(6):1422-1428.
[3] Parfitt JR, Miladinovic Z, Driman DK. Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada -- an epidemiological study from 1964-2002[J]. Can J Gastroenterol. 2006, 20(4):271-276.
[4]王立东.食管和贲门癌癌变多阶段演进机制[J].中华肿瘤防治杂志. 2006, 13(5):321-324.
[5] Spechler S J. Intestinal metaplasia at the gastroesophageal junction[J]. Gastroenterology. 2004, 126(2): 567-575.
[6] Chandrasoma P. Controversies of the cardiac mucosa and Barrett's oesophagus[J]. Histopathology. 2005, 46(4):361-373.
[7] Chlumska A, Boudova L, Benes Z et al. Histopathologic changes in gastroesophageal reflux disease. A study of 126 bioptic and autoptic cases[J]. Cesk Patol. 2007, 43(4):142-147.
[8] Kilgore SP, Ormsby AH, Gramlich TL, et al. The gastric cardia: fact or fiction[J]? Am J Gastroenterol. 2000, 95(4):921-924.
[9] Ormsby AH, Kilgore SP, Goldblum JR, et al. The location and frequency of intestinal metaplasia at the esophagogastric junction in 223 consecutive autopsies: implications for patient treatment and preventive strategies in Barrett's esophagus[J]. Mod Pathol. 2000, 13(6):614-620.
[10] Couvelard A, Cauvin J, Goldfain D, et al. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology[J]. Gut. 2001, 49(6): 761-766.
[11] Kuniyasu H, Yoshida K, Yokosaki H, et al. Expression of cripto, a novel gene of the epidermal growth factor family, in human gastrointestinal carcinomas[J]. Jpn J Cancer Res. 1991, 82(9):969-973.
[12] Johansson J, H?kansson HO, Mellblom L, et al. Prevalence of precancerous and other metaplasia in the distal oesophagus and gastro-oesophageal junction[J]. Scand J Gastroenterol. 2005, 40(8):893-902.
[13] El-Serag HB, Graham DY, Rabeneck L, et al. Prevalence and determinants of histological abnormalities of the gastric cardia in volunteers[J]. Scand J Gastroenterol. 2007, 42(10):1158-1166.
[14] Chandrasoma P, Wickramasinghe K, Ma Y, et al. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia[J]? Dis Esophagus. 2007, 20(1):36-41.
[15] Spechler SJ, Zeroogian JM, Antonioli DA, et al. prevalence of metaplasia at the gastro-esophageal junction[J]. Lancet. 1994, 344(8936):1533-1536.
[16] Peitz U, Malfertheiner P. Z Gastroenterol. Barrett carcinoma:diagnosis, screening, surveillance, endoscopic treatment,prevention [J]. Z Gastroenterol. 2007, 45 (12) :1264-1272.
[17] Shi XY, Bhagwandeen B, Leong AS. CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus[J]. Am J Clin Pathol. 2008, 129(4):571-577.
[18] White NM, Gabril M, Ejeckam G, et al.Barrett's esophagus and cardiac intestinal metaplasia: two conditions within the same spectrum[J]. Can J Gastroenterol. 2008, 22(4):369-375.
[19] Yim HJ, Lee SW, Choung RS. Is cytokeratin immunoreactivity useful in the diagnosis of short-segment Barrett's oesophagus in Korea[J]? Eur J Gastroenterol Hepatol. 2005, 17 (6):611-616.
[20] Dietz J, Chaves-E-Silva S, Meurer L, et al. Short segment Barrett's esophagus and distal gastric intestinal metaplasia[J]. Arq Gastroenterol. 2006, 43(2):117-120.
[21] Roul A, Parenti , Zaninotto G, et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia[J]. Cancer. 2000, 88(11):2520-2526.
[22] Nurgalieva Z, Lowrey A, El-Serag HB. The use of cytokeratin stain to distinguish Barrett's esophagus from contiguous tissues: a systematic review[J]. Dig Dis Sci. 2007, 52 (5):1345-1354.
[23] Semeniuk J, Kaczmarski M. 24-hour esophageal pH monitoring in children with pathological acid gastroesophageal reflux: primary and secondary to food allergy. Part I. Intraesophageal pH values in distal channel; preliminary study and control studies--after 1, 2, 4 and 9 years of clinical observation as well as dietary and pharmacological treatment[J]. Adv Med Sci. 2007, 52:199-205.
[24] Fujita M, Fujimori T, Chiba T. The definition of Barrett's esophagus[J]. Nippon Rinsho. 2005, 63(8):1325-1332.
[25] Souza RF, Shewmake K, Terada LS. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus[J]. Gastroenterology. 2002, 122(2):299-307.
[26] Yen CJ, Izzo JG, Lee DF, et al. Bile acid exposure up-regulates tuberous sclerosis complex 1/ mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma[J]. Cancer Res. 2008, 68(8):2632-2640.
[27] Ransford RA, Jankowski JA. Genetic versus environmental interactions in the oesophagitis-metaplasia-dysplasia-adenocarcinoma sequence (MCS) of Barrett's oesophagus[J]. Acta Gastroenterol Belg. 2000, 63(1):18-21.
[28] Axon AT. Relationship between Helicobacter pylori gastritis, gastric cancer and gastric acid secretion[J]. Adv Med Sci. 2007, 52:55-60.
[29] Egi Y, Ito M, Tanaka S, et al. Role of Helicobacter pylori infection and chronic inflammation in gastric cancer in the cardia[J]. Jpn J Clin Oncol. 2007, 37(5): 365-369.
[30] Shearer CJ, Going JJ, Neilson LJ, et al. Modified classification for adenocarcinoma of the gastro-oesophageal junction[J]. ANZ J Surg. 2007, 77(7):544-549.
[31] Lauwers GY, Mino M, Ban S, et al. Cytokeratins 7 and 20 and mucin core protein expression in esophageal cervical inlet patch[J]. Am J Surg Pathol. 2005, 29(4): 437-442.
[32] Couvelard A, Cauvin JM, Goldfain D, et al. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology[J]. Gut. 2001, 49(6):761-776.
[33] White NM, Gabril M, Ejeckam G, et al. Barrett's esophagus and cardiac intestinal metaplasia: two conditions within the same spectrum[J]. Can J Gastroenterol. 2008, 22(4):369-375.
[34] Radziejewska I, Borzym-Kluczyk M, Kisiel DG, et al. The influence of Helicobacter pylori patients' treatment on MUC 1 content in gastric juice[J]. Hepatogastroenterology. 2008, 55(86-87):1887-1889.
[35] Winn B, Tavares R, Fanion J, et al. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation[J]. Hum Pathol. 2009, 40(3):398-404.
[36] Senapati S, Sharma P, Bafna S, et al. The MUC gene family: their role in the diagnosis and prognosis of gastric cancer[J]. Histol Histopathol. 2008, 23(12):1541-1552.
[37] Kim BW, Kim KM, Lee BI, et al. Expression of trefoil peptides in the subtypes of intestinal metaplasia[J]. Peptides. 2004, 25(5): 779-783.
[38] Mirza ZK, Das KK, Slate J, et al. Gastric intestinal metaplasia as detected by a monoclonal antibody is highly associated with gastric adenocarcinoma[J]. Gut. 2003, 52(6):807-812.
[39] Watari J, Das KK, Amenta PS, et al. Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia. Clin Gastroenterol Hepatol. 2008, 6(4):409-417.
[40] Czyzewska J, Guzińska-Ustymowicz K, Pryczynicz A, et al. Immunohistochemical evaluation of Ki-67, PCNA and MCM2 proteins proliferation index (PI) in advanced gastric cancer[J]. Folia Histochem Cytobiol. 2009, 47(2):289-296.
[41] Gumurdulu D, Erdogan S, Kayaselcuk F, et al. Expression of COX-2, PCNA, Ki-67 and p53 in gastrointestinal stromal tumors and its relationship with histopathological parameters[J]. World J Gastroenterol. 2007, 13(3):426-431.
[42] Sitarz R, Leguit RJ, de Leng WW, et al. Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines[J]. Cell Oncol. 2009, 31(6):475-485.
[43] Oliveira KC, Carvalho ML, Venancio TM, et al. Identification of the Schistosoma mansoni TNF-alpha receptor gene and the effect of human TNF-alpha on the parasite gene expression profile[J]. PLoS Negl Trop Dis. 2009, 3(12): e556.
[44] Simionescu C, M?rg?ritescu C, Surp??eanu M, et al. The study of E-cadherine and CD44 immunoexpression in oral squamous cell carcinoma[J]. Rom J Morphol Embryol. 2008, 49(2):189-193.
[45] Doak SH, Saidely D, Jenkins GJ, et al. Generation of locus-specific probes for interphase fluorescence in situ hybridisation--application in Barrett's esophagus[J]. Exp Mol Pathol. 2004, 77(1):26-33.
[46] Zheng Y, Wang L, Zhang JP, et al. Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma[J]. World J Gastroenterol. 2010, 16(3): 339-344.
[47] Hahn HP, Blount PL, Ayub K, et al. Intestinal Differentiation in Metaplastic, Nongoblet Columnar Epithelium in the Esophagus[J]. Am J Surg Pathol. 2009, 33(7):1006-1015.
[48] Benahmed F, Gross I, Gaunt SJ, et al. Multiple regulatory regions control the complex expression pattern of the mouse Cdx2 homeobox gene[J]. Gastroenterology. 2008, 135(4):1238-1247.
[49] Stringer EJ, Pritchard CA, Beck F. Cdx2 initiates histodifferentiation of the midgut endoderm[J]. FEBS Lett. 2008, 582(17):2555-2560.
[50] Mutoh J, Ishida T, Ishii Y, et al. Effect on the expression of testicular steroidogenic enzymes in fetal mouse by maternal exposure to TCDD[J]. Fukuoka Igaku Zasshi. 2007, 98(5):203-207.
[51] Leung WC, Hessel S, Méplan C, et al. Two common single nucleotide polymorphisms in the gene encoding beta-carotene 15, 15'-monoxygenase alter beta-carotene metabolism in female volunteers[J]. FASEB J. 2009, 23(4):1041-1053.
[52] Tischoff I, Tannapfel A. Barrett's esophagus: can biomarkers predict progression to malignancy[J]? Expert Rev Gastroenterol Hepatol. 2008, 2(5):653-663.
[53] Moriichi K, Watari J, Das KM, et al. Effects of Helicobacter pylori infection on genetic instability, the aberrant CpG island methylation status and the cellular phenotype in Barrett's esophagus in a Japanese population[J]. Int J Cancer. 2009, 124(6):1263-1269.
[54] Alkim C, Savas B, Ensari A, et al. Expression of p53, VEGF, microvessel density, and cyclin-D1 in noncancerous tissue of inflammatory bowel disease[J]. Dig Dis Sci. 2009, 54(9):1979-1984.
[55] Resto VA, Krane JF, Faquin WC, et al. Immunohistochemical distinction of intestinal-type sinonasal adenocarcinoma from metastatic adenocarcinoma of intestinal origin[J]. Ann Otol Rhinol Laryngol. 2006, 115(1):59-64.
[56] Biondi A, Migliore M, Strano G, et al. Clinical biomarkers in esophageal adenocarcinoma[J]. Front Biosci (Elite Ed). 2010, 2:489-494.
[57] Rios-Castellanos E, Sitas F, Shepherd NA, et al. Changing pattern of gastric cancer in Oxfordshire[J]. Gut. 1992, 33(10):1312-1317.
[58] Roul A, Parenti A, Zaninotto G, et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in BE and adenocarcinoma of the gastric cardia[J]. Cancer. 2000, 88(11):2520-2528.
[59] Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus[J]. Gastroenterology. 1995, 109:1541-1546.
[60] Morales T, Sampliner RE, Bhattacharyya A. Intestinal metaplasia of the gastic cardia[J]. Am J Gastroenterol. 1997, 92(3):414-418.
[61] Gulizia JM, Wang H, Antonioli D, et al. Spechler SJ, Zeroogian J, Goyal R, Shahsafaei A, Chen YY, Odze RD. Proliferative characteristics of intestinalized mucosa in the distal esophagus and gastroesophageal junction (short-segment Barrett’s esophagus): a case control study[J]. Hum Pathol. 1999, 30(4):412-418.
[62] Sandic JW, Lanschot JB, Kate FJW, et al. Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction[J]. Cancer. 2000, 88:2429-2437.
[63] Sandic JW, Lanschot JJ, Felius L, et al. Intestinal metaplasia of the esophagus or esophagogastric junction[J]. Am J Clin Pathol. 2002, 117:117-125.
[64] Monnier P, Fontolliet C, Savary M, Ollyo JB. Barrett’s esophagus or columnar epithelium of the lower esophagus[J]. Bailliere’s Clinical Gastroenterology. 1987, 1:769-789.
[65] Spechler SJ, Goyal RK. Barrett’s esophagus[J]. N Engl J Med, 1986, 315:362-71
[66] Clark GW, Ireland AP, Peters JH, et al. Short-segment Barrett’s esophagus: a prevalent complication of gastroesophageal reflux disease with malignant potential[J]. J Gastrointest Surg. 1997, 1:113-122.
[67] Nandurkar S, Talley NJ, Martin CJ, et al. Adams S. Short segment Barrett’s oesophagus: prevalence, diagnosis and associations[J]. Gut. 1997, 40:710-715.
[68]房静远,萧树东.中国慢性胃炎共识意见(2006,上海)解读[J].中华消化杂志. 2007, 27(3):182-184.
[69] Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus[J]. Am J Gastroenterol. 1998, 93:1028-1032.
[70] Weston AP, Krmpotich PT, Cherian R, et al. Prospective long-term endoscopic and histological follow-up of short segment Barrett’s esophagus: comaprison with traditional long segment Barrett’s esophagus[J]. Am J Gastroenterol. 1997, 92(3):407-413.
[71] Steven RD, Tom RD. Columnar mucosa and intestinal metaplasia of the esophagus[J]. Annals of Surgery. 2000, 9:35-41.
[72] Hamilton SR, Smith RRL, Cameron JL. Prevalence and characteristics of Barrett’s esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction[J]. Hum Pathol. 1988, 19:942-948.
[73] Steven RD, Tom RD. Columnar mucosa and intestinal metaplasia of the esophagus[J]. Annals of Surgery. 2000, 9:35-41.?
[74] Nandurkar S, Talley NJ, Martin CJ, et al. Short segment Barrett’s oesophagus: prevalence, diagnosis and associations[J]. Gut. 1997, 40:710-715.
[75] Weston AP, Krmpotich PT, Cherian R, et al. Prospective long-term endoscopic and histological follow-up of short segment Barrett’s esophagus: comaprison with traditional long segment Barrett’s esophagus[J]. Am J Gastroenterol. 1997, 92(3):407-413.
[76] Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus[J]. Am J Gastroenterol. 1998, 93:1028-1032.
[77] Steven RD, Tom RD. Columnar mucosa and intestinal metaplasia of the esophagus[J]. Annals of Surgery. 2000, 9:35-41.
[78]王立东,冯常炜,邹建湘,周琦,裘宋良,陈玉龙.食管癌高发区居民贲门与胃窦上皮病变的比较研究[J].河南医科大学学报. 1997, 32(1):54-57.
[79]周琦,王立东.贲门癌的生物学特征[J].华人消化杂志. 1998, 6(7):636-637.
[80] De Manzoni G, Pedrazzani C, Pasini F, et al. Results of surgical treatment of adenocarcinoma of the gastric cardia[J]. Ann Thorac Surg. 2002, 73(4):1035-1040.
[81]孙秀娣,范金虎,陈汶,等.林州营养干预试验人群恶性肿瘤发病前瞻纵向研究[J].中国医学科学院学报. 2007, 29 (1): 87- 92.
[82]王立东,高文俊,杨万才,等.林州市人民医院9年间食管癌,贲门癌3933例分析[J].河南医科大学学报. 1997, 32(1): 9-11.
[83] Rapp UR, Ceteci F, Schreck R. Oncogene-induced plasticity and cancer stem cells[J]. Cell Cycle. 2008, 7(1): 45-51.
[84] Port RV, Arnold J, Kerr D, et al. Cultural enhancement of a clinical service to meet the needs of indigenous people; genetic service development in response to issues for New Zealand Maori[J]. Clin Genet. 2008, 73(2): 132-138.
[85] Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis[J]. Oncogene. 2007, 26(47): 6697-6714.
[86] Odze RD. Unraveling the mystery of the gastroesophageal junction: a pathologist's perspective[J]. Am J Gastroenterol. 2005, 100(8):1853-1867.
[87] Flucke U, Steinborn E, Dries V, et al. Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach[J]. Histopathology. 2003, 43(2):127-134.
[88] Yagi K, Nakamura A, Sekine A, et al. An early cancer of the gastric cardia arising from carditis after long-term gastroesophageal reflux disease in the absence of Helicobacter pylori infection. Gastroenterol Hepatol[J]. 2002, 17(11):1236-1238.
[89] Srivastava A, Odze RD, Lauwers GY, et al. Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia.Am J Surg Pathol[J]. 2007, 31(11):1733-1741.
[90] Chaabouni H, Haouet S, Cheikh I, et al. Intestinal metaplasia at the gastroesophageal junction - epidemiologic and histologic aspects. Report of 164 cases[J]. Tunis Med. 2001, 79(6-7):353-360.
[91] Wolf C, Seldenrijk CA, Timmer R, et al. Epidemiological, clinical, and histological characteristics of intestinal metaplasia at the oesophagogastric junction compared to short segments of columnar-lined oesophagus[J]. Eur J Gastroenterol Hepatol. 2001, 13(2):113-120.
[92] Coats S, Flanagan WM, Nourse J, et al. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle[J]. Science. 1996, 272(5263):877-880.
[93] Robert L. Zimmerman, Kiron M. et al. The Clinical Utility of the Das-1 Monoclonal Antibody in Identifying Adenocarcinoma of the Colon Metastatic to the Liver in Fine-Needle Aspiration Tissue[J]. Cancer. 2002, 96(6): 370-373.
[94] Thim L, Jorgensen KH, Jorgensen KD. Pancreatic spasmolytic polypeptide (PSP) II. Radioimmunological determination of PSP in porcine tissues, plasma and pancreatic juice[J]. Regul Pept. 1982, 3(3-4): 221-230.
[95] Hanby AM, Poulsom R, Singh S, et al. Spasmolytic polypeptide is a major antral peptide:distribution of the trefoil peptides human spasmolytic polypeptide and pS2 in the stomach[J]. Gastroenterology. 1993, 105(4): 1110-1116.
[96] Tomasetto C, Rio MC, Gautier C, et al. hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma[J]. EMBO J. 1990, 9(2): 407-414.
[97] Leung WL, Yu J, Chan FK, et al. Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues[J]. J Pathol. 2002, 197(5): 582-588.
[98] Yamachika T, Werther JL, Bodian C, et al. Intestinal Trefoil Factor[J]. Clin Cancer Res. 2002, 8(5): 1092-1099.
[99] Rose DS , Maddox PH , Brown DC. Which proliferation markers for routine immunohistology A comparison of five antibodies[J]. J Clin Pathol. 1994, (11): 1010-1014.
[100]王立东,李吉林,张彦霞等.河南贲门癌高发区贲门癌发生部位分析[J].郑州大学学报(医学版). 2007, 42(3): 389-393.
[101]高社干,冯笑山,马保根等.贲门癌癌旁和无症状人群贲门黏膜活检组织肠上皮化生检测[J].郑州大学学报(医学版). 2006, 41(1): 41-44.
[102] Z K Mirza, K K Das, J Slate, et al. Gastric intestinal metaplasia as detected by a monoclonal antibody is highly associated with gastric adenocarcinoma[J]. Gut. 2003, 52(6): 807-812.
[103] FornéMontserrat, Fernández-Ba?ares Fernando, González-Mínguez Clarisa, et al. Lack of clinical usefulness of Das-1 monoclonal antibody and mucin expression as risk markers of gastric carcinoma in patients with gastric intestinal metaplasia[J]. Am J Clin Pathol. 2009, 131(1):99-105.
[104] Paulsen FP, Woon CW, Varoga D, et al. Intestinal trefoil factor/TFF3 promotes re-epithelialization of corneal wounds[J]. J Biol Chem. 2008, 283 (19): 13418-13427.
[105] Uwe Dürer, Roland Hartig, Susanne Bang, et al. TFF3 and EGF Induce Different Migration Patterns of Intestinal Epithelial Cells In Vitro and Trigger Increased Internalization of E-cadherin[J]. Cell Physiol Biochem. 2007, 20: 329-346.
[106] Furuta GT, Turner JR, Taylor CT, et al. Hypoxia-inducible factor 1-dependent induction of intestimal trefoil pretects battier function during hypoxia[J]. J Exp. 2001, 193(9):1027-1034.
[107] Storesund T, Hayashi K, Kolltveit KM, et al. Salivary trefoil factor 3 enhances migration of oral keratinocytes[J]. Eur J Oral Sci. 2008, 116(2):135-140.
[108] Babyatsky M, Lin J, Yio X, et al. Trefoil factor-3 expression in human colon cancer liver metastasis[J]. Clin Exp Metastasis. 2009, 26(2):143-151.
[109]张秋宁,马力.三叶因子3在胃癌组织中的表达及与血管形成的关系[J].现代肿瘤医学.2005, 13: 42-44.
[110] Taupin D, Ooi D, Yeomans N, et al. Conserved expression of intestimal trefoil factor in the human colonic adenoma-carcinoma sequence[J]. Lab Investig. 1996, 75: 25-32.
[111] Madsen J, Nielsen O, Torn?e I, et al. Tissue localization of human trefoil factors 1, 2, and 3[J]. J Histochem Cytochem. 2007, 55(5): 505-513.
[2] Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by histology, United States, 1998-2003[J]. Int J Cancer. 2008, 123(6):1422-1428.
[3] Parfitt JR, Miladinovic Z, Driman DK. Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada -- an epidemiological study from 1964-2002[J]. Can J Gastroenterol. 2006, 20(4):271-276.
[4]王立东.食管和贲门癌癌变多阶段演进机制[J].中华肿瘤防治杂志. 2006, 13(5):321-324.
[5] Spechler S J. Intestinal metaplasia at the gastroesophageal junction[J]. Gastroenterology. 2004, 126(2): 567-575.
[6] Chandrasoma P. Controversies of the cardiac mucosa and Barrett's oesophagus[J]. Histopathology. 2005, 46(4):361-373.
[7] Chlumska A, Boudova L, Benes Z et al. Histopathologic changes in gastroesophageal reflux disease. A study of 126 bioptic and autoptic cases[J]. Cesk Patol. 2007, 43(4):142-147.
[8] Kilgore SP, Ormsby AH, Gramlich TL, et al. The gastric cardia: fact or fiction[J]? Am J Gastroenterol. 2000, 95(4):921-924.
[9] Ormsby AH, Kilgore SP, Goldblum JR, et al. The location and frequency of intestinal metaplasia at the esophagogastric junction in 223 consecutive autopsies: implications for patient treatment and preventive strategies in Barrett's esophagus[J]. Mod Pathol. 2000, 13(6):614-620.
[10] Couvelard A, Cauvin J, Goldfain D, et al. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology[J]. Gut. 2001, 49(6): 761-766.
[11] Kuniyasu H, Yoshida K, Yokosaki H, et al. Expression of cripto, a novel gene of the epidermal growth factor family, in human gastrointestinal carcinomas[J]. Jpn J Cancer Res. 1991, 82(9):969-973.
[12] Johansson J, H?kansson HO, Mellblom L, et al. Prevalence of precancerous and other metaplasia in the distal oesophagus and gastro-oesophageal junction[J]. Scand J Gastroenterol. 2005, 40(8):893-902.
[13] El-Serag HB, Graham DY, Rabeneck L, et al. Prevalence and determinants of histological abnormalities of the gastric cardia in volunteers[J]. Scand J Gastroenterol. 2007, 42(10):1158-1166.
[14] Chandrasoma P, Wickramasinghe K, Ma Y, et al. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia[J]? Dis Esophagus. 2007, 20(1):36-41.
[15] Spechler SJ, Zeroogian JM, Antonioli DA, et al. prevalence of metaplasia at the gastro-esophageal junction[J]. Lancet. 1994, 344(8936):1533-1536.
[16] Peitz U, Malfertheiner P. Z Gastroenterol. Barrett carcinoma:diagnosis, screening, surveillance, endoscopic treatment,prevention [J]. Z Gastroenterol. 2007, 45 (12) :1264-1272.
[17] Shi XY, Bhagwandeen B, Leong AS. CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus[J]. Am J Clin Pathol. 2008, 129(4):571-577.
[18] White NM, Gabril M, Ejeckam G, et al.Barrett's esophagus and cardiac intestinal metaplasia: two conditions within the same spectrum[J]. Can J Gastroenterol. 2008, 22(4):369-375.
[19] Yim HJ, Lee SW, Choung RS. Is cytokeratin immunoreactivity useful in the diagnosis of short-segment Barrett's oesophagus in Korea[J]? Eur J Gastroenterol Hepatol. 2005, 17 (6):611-616.
[20] Dietz J, Chaves-E-Silva S, Meurer L, et al. Short segment Barrett's esophagus and distal gastric intestinal metaplasia[J]. Arq Gastroenterol. 2006, 43(2):117-120.
[21] Roul A, Parenti , Zaninotto G, et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia[J]. Cancer. 2000, 88(11):2520-2526.
[22] Nurgalieva Z, Lowrey A, El-Serag HB. The use of cytokeratin stain to distinguish Barrett's esophagus from contiguous tissues: a systematic review[J]. Dig Dis Sci. 2007, 52 (5):1345-1354.
[23] Semeniuk J, Kaczmarski M. 24-hour esophageal pH monitoring in children with pathological acid gastroesophageal reflux: primary and secondary to food allergy. Part I. Intraesophageal pH values in distal channel; preliminary study and control studies--after 1, 2, 4 and 9 years of clinical observation as well as dietary and pharmacological treatment[J]. Adv Med Sci. 2007, 52:199-205.
[24] Fujita M, Fujimori T, Chiba T. The definition of Barrett's esophagus[J]. Nippon Rinsho. 2005, 63(8):1325-1332.
[25] Souza RF, Shewmake K, Terada LS. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus[J]. Gastroenterology. 2002, 122(2):299-307.
[26] Yen CJ, Izzo JG, Lee DF, et al. Bile acid exposure up-regulates tuberous sclerosis complex 1/ mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma[J]. Cancer Res. 2008, 68(8):2632-2640.
[27] Ransford RA, Jankowski JA. Genetic versus environmental interactions in the oesophagitis-metaplasia-dysplasia-adenocarcinoma sequence (MCS) of Barrett's oesophagus[J]. Acta Gastroenterol Belg. 2000, 63(1):18-21.
[28] Axon AT. Relationship between Helicobacter pylori gastritis, gastric cancer and gastric acid secretion[J]. Adv Med Sci. 2007, 52:55-60.
[29] Egi Y, Ito M, Tanaka S, et al. Role of Helicobacter pylori infection and chronic inflammation in gastric cancer in the cardia[J]. Jpn J Clin Oncol. 2007, 37(5): 365-369.
[30] Shearer CJ, Going JJ, Neilson LJ, et al. Modified classification for adenocarcinoma of the gastro-oesophageal junction[J]. ANZ J Surg. 2007, 77(7):544-549.
[31] Lauwers GY, Mino M, Ban S, et al. Cytokeratins 7 and 20 and mucin core protein expression in esophageal cervical inlet patch[J]. Am J Surg Pathol. 2005, 29(4): 437-442.
[32] Couvelard A, Cauvin JM, Goldfain D, et al. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology[J]. Gut. 2001, 49(6):761-776.
[33] White NM, Gabril M, Ejeckam G, et al. Barrett's esophagus and cardiac intestinal metaplasia: two conditions within the same spectrum[J]. Can J Gastroenterol. 2008, 22(4):369-375.
[34] Radziejewska I, Borzym-Kluczyk M, Kisiel DG, et al. The influence of Helicobacter pylori patients' treatment on MUC 1 content in gastric juice[J]. Hepatogastroenterology. 2008, 55(86-87):1887-1889.
[35] Winn B, Tavares R, Fanion J, et al. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation[J]. Hum Pathol. 2009, 40(3):398-404.
[36] Senapati S, Sharma P, Bafna S, et al. The MUC gene family: their role in the diagnosis and prognosis of gastric cancer[J]. Histol Histopathol. 2008, 23(12):1541-1552.
[37] Kim BW, Kim KM, Lee BI, et al. Expression of trefoil peptides in the subtypes of intestinal metaplasia[J]. Peptides. 2004, 25(5): 779-783.
[38] Mirza ZK, Das KK, Slate J, et al. Gastric intestinal metaplasia as detected by a monoclonal antibody is highly associated with gastric adenocarcinoma[J]. Gut. 2003, 52(6):807-812.
[39] Watari J, Das KK, Amenta PS, et al. Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia. Clin Gastroenterol Hepatol. 2008, 6(4):409-417.
[40] Czyzewska J, Guzińska-Ustymowicz K, Pryczynicz A, et al. Immunohistochemical evaluation of Ki-67, PCNA and MCM2 proteins proliferation index (PI) in advanced gastric cancer[J]. Folia Histochem Cytobiol. 2009, 47(2):289-296.
[41] Gumurdulu D, Erdogan S, Kayaselcuk F, et al. Expression of COX-2, PCNA, Ki-67 and p53 in gastrointestinal stromal tumors and its relationship with histopathological parameters[J]. World J Gastroenterol. 2007, 13(3):426-431.
[42] Sitarz R, Leguit RJ, de Leng WW, et al. Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines[J]. Cell Oncol. 2009, 31(6):475-485.
[43] Oliveira KC, Carvalho ML, Venancio TM, et al. Identification of the Schistosoma mansoni TNF-alpha receptor gene and the effect of human TNF-alpha on the parasite gene expression profile[J]. PLoS Negl Trop Dis. 2009, 3(12): e556.
[44] Simionescu C, M?rg?ritescu C, Surp??eanu M, et al. The study of E-cadherine and CD44 immunoexpression in oral squamous cell carcinoma[J]. Rom J Morphol Embryol. 2008, 49(2):189-193.
[45] Doak SH, Saidely D, Jenkins GJ, et al. Generation of locus-specific probes for interphase fluorescence in situ hybridisation--application in Barrett's esophagus[J]. Exp Mol Pathol. 2004, 77(1):26-33.
[46] Zheng Y, Wang L, Zhang JP, et al. Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma[J]. World J Gastroenterol. 2010, 16(3): 339-344.
[47] Hahn HP, Blount PL, Ayub K, et al. Intestinal Differentiation in Metaplastic, Nongoblet Columnar Epithelium in the Esophagus[J]. Am J Surg Pathol. 2009, 33(7):1006-1015.
[48] Benahmed F, Gross I, Gaunt SJ, et al. Multiple regulatory regions control the complex expression pattern of the mouse Cdx2 homeobox gene[J]. Gastroenterology. 2008, 135(4):1238-1247.
[49] Stringer EJ, Pritchard CA, Beck F. Cdx2 initiates histodifferentiation of the midgut endoderm[J]. FEBS Lett. 2008, 582(17):2555-2560.
[50] Mutoh J, Ishida T, Ishii Y, et al. Effect on the expression of testicular steroidogenic enzymes in fetal mouse by maternal exposure to TCDD[J]. Fukuoka Igaku Zasshi. 2007, 98(5):203-207.
[51] Leung WC, Hessel S, Méplan C, et al. Two common single nucleotide polymorphisms in the gene encoding beta-carotene 15, 15'-monoxygenase alter beta-carotene metabolism in female volunteers[J]. FASEB J. 2009, 23(4):1041-1053.
[52] Tischoff I, Tannapfel A. Barrett's esophagus: can biomarkers predict progression to malignancy[J]? Expert Rev Gastroenterol Hepatol. 2008, 2(5):653-663.
[53] Moriichi K, Watari J, Das KM, et al. Effects of Helicobacter pylori infection on genetic instability, the aberrant CpG island methylation status and the cellular phenotype in Barrett's esophagus in a Japanese population[J]. Int J Cancer. 2009, 124(6):1263-1269.
[54] Alkim C, Savas B, Ensari A, et al. Expression of p53, VEGF, microvessel density, and cyclin-D1 in noncancerous tissue of inflammatory bowel disease[J]. Dig Dis Sci. 2009, 54(9):1979-1984.
[55] Resto VA, Krane JF, Faquin WC, et al. Immunohistochemical distinction of intestinal-type sinonasal adenocarcinoma from metastatic adenocarcinoma of intestinal origin[J]. Ann Otol Rhinol Laryngol. 2006, 115(1):59-64.
[56] Biondi A, Migliore M, Strano G, et al. Clinical biomarkers in esophageal adenocarcinoma[J]. Front Biosci (Elite Ed). 2010, 2:489-494.
[57] Rios-Castellanos E, Sitas F, Shepherd NA, et al. Changing pattern of gastric cancer in Oxfordshire[J]. Gut. 1992, 33(10):1312-1317.
[58] Roul A, Parenti A, Zaninotto G, et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in BE and adenocarcinoma of the gastric cardia[J]. Cancer. 2000, 88(11):2520-2528.
[59] Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus[J]. Gastroenterology. 1995, 109:1541-1546.
[60] Morales T, Sampliner RE, Bhattacharyya A. Intestinal metaplasia of the gastic cardia[J]. Am J Gastroenterol. 1997, 92(3):414-418.
[61] Gulizia JM, Wang H, Antonioli D, et al. Spechler SJ, Zeroogian J, Goyal R, Shahsafaei A, Chen YY, Odze RD. Proliferative characteristics of intestinalized mucosa in the distal esophagus and gastroesophageal junction (short-segment Barrett’s esophagus): a case control study[J]. Hum Pathol. 1999, 30(4):412-418.
[62] Sandic JW, Lanschot JB, Kate FJW, et al. Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction[J]. Cancer. 2000, 88:2429-2437.
[63] Sandic JW, Lanschot JJ, Felius L, et al. Intestinal metaplasia of the esophagus or esophagogastric junction[J]. Am J Clin Pathol. 2002, 117:117-125.
[64] Monnier P, Fontolliet C, Savary M, Ollyo JB. Barrett’s esophagus or columnar epithelium of the lower esophagus[J]. Bailliere’s Clinical Gastroenterology. 1987, 1:769-789.
[65] Spechler SJ, Goyal RK. Barrett’s esophagus[J]. N Engl J Med, 1986, 315:362-71
[66] Clark GW, Ireland AP, Peters JH, et al. Short-segment Barrett’s esophagus: a prevalent complication of gastroesophageal reflux disease with malignant potential[J]. J Gastrointest Surg. 1997, 1:113-122.
[67] Nandurkar S, Talley NJ, Martin CJ, et al. Adams S. Short segment Barrett’s oesophagus: prevalence, diagnosis and associations[J]. Gut. 1997, 40:710-715.
[68]房静远,萧树东.中国慢性胃炎共识意见(2006,上海)解读[J].中华消化杂志. 2007, 27(3):182-184.
[69] Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus[J]. Am J Gastroenterol. 1998, 93:1028-1032.
[70] Weston AP, Krmpotich PT, Cherian R, et al. Prospective long-term endoscopic and histological follow-up of short segment Barrett’s esophagus: comaprison with traditional long segment Barrett’s esophagus[J]. Am J Gastroenterol. 1997, 92(3):407-413.
[71] Steven RD, Tom RD. Columnar mucosa and intestinal metaplasia of the esophagus[J]. Annals of Surgery. 2000, 9:35-41.
[72] Hamilton SR, Smith RRL, Cameron JL. Prevalence and characteristics of Barrett’s esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction[J]. Hum Pathol. 1988, 19:942-948.
[73] Steven RD, Tom RD. Columnar mucosa and intestinal metaplasia of the esophagus[J]. Annals of Surgery. 2000, 9:35-41.?
[74] Nandurkar S, Talley NJ, Martin CJ, et al. Short segment Barrett’s oesophagus: prevalence, diagnosis and associations[J]. Gut. 1997, 40:710-715.
[75] Weston AP, Krmpotich PT, Cherian R, et al. Prospective long-term endoscopic and histological follow-up of short segment Barrett’s esophagus: comaprison with traditional long segment Barrett’s esophagus[J]. Am J Gastroenterol. 1997, 92(3):407-413.
[76] Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus[J]. Am J Gastroenterol. 1998, 93:1028-1032.
[77] Steven RD, Tom RD. Columnar mucosa and intestinal metaplasia of the esophagus[J]. Annals of Surgery. 2000, 9:35-41.
[78]王立东,冯常炜,邹建湘,周琦,裘宋良,陈玉龙.食管癌高发区居民贲门与胃窦上皮病变的比较研究[J].河南医科大学学报. 1997, 32(1):54-57.
[79]周琦,王立东.贲门癌的生物学特征[J].华人消化杂志. 1998, 6(7):636-637.
[80] De Manzoni G, Pedrazzani C, Pasini F, et al. Results of surgical treatment of adenocarcinoma of the gastric cardia[J]. Ann Thorac Surg. 2002, 73(4):1035-1040.
[81]孙秀娣,范金虎,陈汶,等.林州营养干预试验人群恶性肿瘤发病前瞻纵向研究[J].中国医学科学院学报. 2007, 29 (1): 87- 92.
[82]王立东,高文俊,杨万才,等.林州市人民医院9年间食管癌,贲门癌3933例分析[J].河南医科大学学报. 1997, 32(1): 9-11.
[83] Rapp UR, Ceteci F, Schreck R. Oncogene-induced plasticity and cancer stem cells[J]. Cell Cycle. 2008, 7(1): 45-51.
[84] Port RV, Arnold J, Kerr D, et al. Cultural enhancement of a clinical service to meet the needs of indigenous people; genetic service development in response to issues for New Zealand Maori[J]. Clin Genet. 2008, 73(2): 132-138.
[85] Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis[J]. Oncogene. 2007, 26(47): 6697-6714.
[86] Odze RD. Unraveling the mystery of the gastroesophageal junction: a pathologist's perspective[J]. Am J Gastroenterol. 2005, 100(8):1853-1867.
[87] Flucke U, Steinborn E, Dries V, et al. Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach[J]. Histopathology. 2003, 43(2):127-134.
[88] Yagi K, Nakamura A, Sekine A, et al. An early cancer of the gastric cardia arising from carditis after long-term gastroesophageal reflux disease in the absence of Helicobacter pylori infection. Gastroenterol Hepatol[J]. 2002, 17(11):1236-1238.
[89] Srivastava A, Odze RD, Lauwers GY, et al. Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia.Am J Surg Pathol[J]. 2007, 31(11):1733-1741.
[90] Chaabouni H, Haouet S, Cheikh I, et al. Intestinal metaplasia at the gastroesophageal junction - epidemiologic and histologic aspects. Report of 164 cases[J]. Tunis Med. 2001, 79(6-7):353-360.
[91] Wolf C, Seldenrijk CA, Timmer R, et al. Epidemiological, clinical, and histological characteristics of intestinal metaplasia at the oesophagogastric junction compared to short segments of columnar-lined oesophagus[J]. Eur J Gastroenterol Hepatol. 2001, 13(2):113-120.
[92] Coats S, Flanagan WM, Nourse J, et al. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle[J]. Science. 1996, 272(5263):877-880.
[93] Robert L. Zimmerman, Kiron M. et al. The Clinical Utility of the Das-1 Monoclonal Antibody in Identifying Adenocarcinoma of the Colon Metastatic to the Liver in Fine-Needle Aspiration Tissue[J]. Cancer. 2002, 96(6): 370-373.
[94] Thim L, Jorgensen KH, Jorgensen KD. Pancreatic spasmolytic polypeptide (PSP) II. Radioimmunological determination of PSP in porcine tissues, plasma and pancreatic juice[J]. Regul Pept. 1982, 3(3-4): 221-230.
[95] Hanby AM, Poulsom R, Singh S, et al. Spasmolytic polypeptide is a major antral peptide:distribution of the trefoil peptides human spasmolytic polypeptide and pS2 in the stomach[J]. Gastroenterology. 1993, 105(4): 1110-1116.
[96] Tomasetto C, Rio MC, Gautier C, et al. hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma[J]. EMBO J. 1990, 9(2): 407-414.
[97] Leung WL, Yu J, Chan FK, et al. Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues[J]. J Pathol. 2002, 197(5): 582-588.
[98] Yamachika T, Werther JL, Bodian C, et al. Intestinal Trefoil Factor[J]. Clin Cancer Res. 2002, 8(5): 1092-1099.
[99] Rose DS , Maddox PH , Brown DC. Which proliferation markers for routine immunohistology A comparison of five antibodies[J]. J Clin Pathol. 1994, (11): 1010-1014.
[100]王立东,李吉林,张彦霞等.河南贲门癌高发区贲门癌发生部位分析[J].郑州大学学报(医学版). 2007, 42(3): 389-393.
[101]高社干,冯笑山,马保根等.贲门癌癌旁和无症状人群贲门黏膜活检组织肠上皮化生检测[J].郑州大学学报(医学版). 2006, 41(1): 41-44.
[102] Z K Mirza, K K Das, J Slate, et al. Gastric intestinal metaplasia as detected by a monoclonal antibody is highly associated with gastric adenocarcinoma[J]. Gut. 2003, 52(6): 807-812.
[103] FornéMontserrat, Fernández-Ba?ares Fernando, González-Mínguez Clarisa, et al. Lack of clinical usefulness of Das-1 monoclonal antibody and mucin expression as risk markers of gastric carcinoma in patients with gastric intestinal metaplasia[J]. Am J Clin Pathol. 2009, 131(1):99-105.
[104] Paulsen FP, Woon CW, Varoga D, et al. Intestinal trefoil factor/TFF3 promotes re-epithelialization of corneal wounds[J]. J Biol Chem. 2008, 283 (19): 13418-13427.
[105] Uwe Dürer, Roland Hartig, Susanne Bang, et al. TFF3 and EGF Induce Different Migration Patterns of Intestinal Epithelial Cells In Vitro and Trigger Increased Internalization of E-cadherin[J]. Cell Physiol Biochem. 2007, 20: 329-346.
[106] Furuta GT, Turner JR, Taylor CT, et al. Hypoxia-inducible factor 1-dependent induction of intestimal trefoil pretects battier function during hypoxia[J]. J Exp. 2001, 193(9):1027-1034.
[107] Storesund T, Hayashi K, Kolltveit KM, et al. Salivary trefoil factor 3 enhances migration of oral keratinocytes[J]. Eur J Oral Sci. 2008, 116(2):135-140.
[108] Babyatsky M, Lin J, Yio X, et al. Trefoil factor-3 expression in human colon cancer liver metastasis[J]. Clin Exp Metastasis. 2009, 26(2):143-151.
[109]张秋宁,马力.三叶因子3在胃癌组织中的表达及与血管形成的关系[J].现代肿瘤医学.2005, 13: 42-44.
[110] Taupin D, Ooi D, Yeomans N, et al. Conserved expression of intestimal trefoil factor in the human colonic adenoma-carcinoma sequence[J]. Lab Investig. 1996, 75: 25-32.
[111] Madsen J, Nielsen O, Torn?e I, et al. Tissue localization of human trefoil factors 1, 2, and 3[J]. J Histochem Cytochem. 2007, 55(5): 505-513.